Evidence map›Paper›PMID 35619550›Full record

ArticleJournal of pineal research2022

Melatonin and andrographolide synergize to inhibit the colospheroid phenotype by targeting Wnt/beta-catenin signaling.

Daniil Sokolov, Neha Sharda, Banabihari Giri, Md Sazzad Hassan, Damandeep Singh, Agnieszka Tarasiewicz, Charity Lohr, Urs von Holzen, Tibor Kristian, Jaylyn Waddell and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of pineal research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Daniil SokolovDepartment of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Neha ShardaDepartment of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Banabihari GiriDivision of Virology and Immunology, Maryland Department of Health, Baltimore, Maryland, USA.
Md Sazzad HassanDepartment of Surgery, Indiana University School of Medicine, South Bend, Indiana, USA.
Damandeep SinghDepartment of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Agnieszka TarasiewiczDepartment of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Charity LohrDepartment of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Urs von HolzenDepartment of Surgery, Indiana University School of Medicine, South Bend, Indiana, USA.
Tibor KristianOffice of Research and Development, VAMHCS, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Jaylyn WaddellDepartment of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Russel J ReiterDepartment of Cell Systems and Anatomy, UT Health San Antonio, San Antonio, Texas, USA.ORCID http://orcid.org/0000-0001-6763-4225
Hafiz AhmedTherapeutic Division, GlycoMantra Inc, Baltimore, Maryland, USA.
Aditi BanerjeeDepartment of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID http://orcid.org/0000-0003-1608-2998
University of Maryland, Baltimore · USGlycoMimetics (United States) · USNorthern Indiana Cancer Research Consortium · USThe University of Texas Health Science Center at San Antonio · USUniversity of Basel · CH

Funding

Using NAD+ precursor for treatment of global cerebral ischemiaR01NS119275 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI KRISTIAN, TIBOR · 2021 to 2025
$1.9M
The role of nicotinamide mononucleotide dependent mitochondrial reactive oxygen species generation in acute brain injuryI01BX004895 · VA · BALTIMORE VA MEDICAL CENTER · PI KRISTIAN, TIBOR · 2020 to 2024
–
BLRD VA I01 BX004895NIH NINDS R01NS119275NINDS NIH HHS R01 NS119275
6 · The paper itself

Abstract

β-catenin signaling, and angiogenesis are associated with colospheroid (CSC), development. CSCs, spheroids derived from colon cancer cells, are responsible for metastasis, drug resistance, and disease recurrence. Whether dysregulating β-catenin and inhibiting angiogenesis reduce CSC growth is unknown. In this study, the molecular mechanism of CSC growth inhibition was evaluated using a novel combination of melatonin (MLT) and andrographolide (AGP). These drugs have anticarcinogenic, antioxidant, and antimetastatic properties. CSCs were obtained from two metastatic colon cancer cell lines (HT29 and HCT-15). The viability and stemness were monitored (FDA propidium iodide staining and immunoblot for CD44, CD133, Nanog, Sox2, and Oct4). The drug combination synergistically diminished stemness via increased reactive oxygen species (ROS) levels, reduced mitochondrial membrane potential and ATP level. MLT + AGP induced cell death by inhibiting β-catenin expression and its downregulatory signals, Cyclin D1, c-Myc. MLT + AGP treated cells exhibited translocation of phospho-β-catenin to the nucleus and dephosphorylated-β-catenin. Downregulation of β-catenin activation and its transcription factors (TCF4 and LEF1) and GTP binding/G-protein related activity were found in the dual therapy. Angiogenic inhibition is consistent with downregulation of VEGF messenger RNA transcripts (VEGF189), phosphorylated VEGF receptor protein expression, matrigel invasion, and capillary tube inhibition. In vivo, the intravenous injection of MLT + AGP slowed HT29 metastatic colon cancer. Histopathology indicated significant reduction in microvascular density and tumor index. Immunohistochemistry for caspase 7, and β-catenin found increased apoptosis and downregulation of β-catenin signals. The mechanism(s) of decreased colospheroids growth were the inhibition of the Wnt/β-catenin pathway. Our results provide a rationale for using MLT in combination with AGP for the inhibition of CRCs.

Indexed as

Colonic NeoplasmsMelatoninbeta CateninCell Line, TumorCell ProliferationDiterpenesHumansNeoplastic Stem CellsPhenotypeWnt Signaling Pathwayandrographolidebeta CateninDiterpenesMelatoninandrographolideangiogenesiscolospheroidsmelatoninWnt/β-catenin signalsxenograft

Identifiers

PMID35619550
PMCPMC9288490
OpenAlexW4281935774

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.